Proteus Biomedical: Using Computers to Manage Chronic Diseases
Modeled after advanced computers used in industrial applications, such as automotives, Proteus Biomedical hopes to bring what it calls pervasive computing to treat chronic conditions such as chronic heart failure and, later on, others. The company's approach combines device and drug therapy in an innovative kind of combination products; in the process, says Proteus, it will define not just a new category of medical products but also shape a new competitive landscape.
by David Cassak
For nearly a decade, one of the hottest topics in medical devices has been drug/device convergence: combining in a single product the features and benefits of both device and pharmaceutical...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
Named after the Norse goddess of fertility, Freya Biosciences is mapping the reproductive microbiome with a host of women's health indications as the final destination.
Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.
Avacta's approach to drug delivery is showing how 'masked' chemotherapy can dramatically improve safety profiles while maintaining or enhancing efficacy where it matters most.
The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.
Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.
Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.
